Our study indicated that after knockdown of RRM1/2, RT112-Gr bladder cancer cell lines sensitive to gemcitabine again, indicating the overexpression of RRM was associated with gemcitabine resistance, and might be a novel candidate biomarker for gemcitabine resistance. Here, RRM1 is linked to urinary bladder carcinoma.